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Background. Bacillus anthracis, the etiologic agent of inhalational anthrax, is a facultative intracellular pathogen. Despite
appropriate antimicrobial therapy, the mortality from inhalational anthrax approaches 45%, underscoring the need for better
adjuvant therapies. The variable latency between exposure and development of disease suggests an important role for the
host’s innate immune response. Type I and Type II Interferons (IFN) are prominent members of the host innate immune
response and are required for control of intracellular pathogens. We have previously described a protective role for exogenous
Type I and Type II IFNs in attenuating intracellular B.anthracis germination and macrophage cell death in vitro. Methodology
and Principal Findings. We sought to extend these findings in an in vivo model of inhalational anthrax, utilizing the Sterne
strain (34F2)o fB.anthracis. Mice devoid of STAT1, a component of IFN-a and IFN-c signaling, had a trend towards increased
mortality, bacterial germination and extrapulmonary spread of B.anthracis at 24 hrs. This was associated with impaired IL-6, IL-
10 and IL-12 production. However, administration of exogenous IFN-c, and to a lesser extent IFN-a, at the time of infection,
markedly increased lethality. While IFNs were able to reduce the fraction of germinated spores within the lung, they increased
both the local and systemic inflammatory response manifest by increases in IL-12 and reductions in IL-10. This was associated
with an increase in extrapulmonary dissemination. The mechanism of IFN mediated inflammation appears to be in part due to
STAT1 independent signaling. Conclusions. In conclusion, while endogenous IFNs are essential for control of B.anthracis
germination and lethality, administration of exogenous IFNs appear to increase the local inflammatory response, thereby
increasing mortality.
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INTRODUCTION
Bacillus anthracis (B.anthracis), a gram positive aerobic spore-forming
bacilli, is found ubiquitously in animals and soil and, depending on
the site of entry, causes a wide array of diseases in humans [1].
Inhalation of B.anthracis spores results in mediastinal hemorrhage,
pneumonia and sepsis with a high mortality in spite of appropriate
anti-microbial therapy [2]. While vaccination of animals and
humans in animal husbandry had nearly eliminated this disease in
the United States, anthrax has gained renewed attention as
a bioterrorism agent. During the attacks of 2001, 11 people
contracted inhalation anthrax, 11 contacted cutaneous anthrax,
and hundreds of individuals were exposed to potentially dangerous
level of spores [2]. In spite of adequate antimicrobial therapy,
inhalational anthrax had a 45% mortality, underscoring the need
for better adjuvant therapies in case of future outbreaks [2].
Once inhaled, B.anthracis spores are ingested by alveolar
macrophages. Spores subsequently germinate into the vegetative
form, with resultant production of both Lethal Toxin (LeTx) and
Edema Toxin. Lethal Toxin, a zinc metallopeptidase, is capable of
disrupting numerous intracellular signaling cascades, including
cleavage of MAP kinase kinase (MKK) family members [3]. This
has numerous effects on the host including suppression of cytokine
production and impairment in macrophage phagocytic capability
[4–6]. However, the long and variable latency between exposure
and development of disseminated disease in humans and primates
suggests this disruption is incomplete in nature and raises the
possibility that modulation of innate immune pathways as an
important target for immunomodulatory therapy [7].
Interferons (IFN) play a prominent role in the host innate
immune response to intracellular pathogens. There are two broad
categories of IFNs, Type I (IFN-a, IFN-b) and Type II (IFN-c).
Type I IFNs, while traditionally thought to be involved in the host
response to viral infections are also involved during the initial
stages of infection with intracellular pathogens such as Mycobac-
terium tuberculosis [8,9]. Interferon-c is the prototypical Type II IFN.
Multiple studies show a prominent role for IFN-c in controlling
intracellular infections including M.tuberculosis and L.monocytogenes
[10–14]. Both IFN-a and IFN-c have been used successfully as
immunoadjuvants for pulmonary tuberculosis with treated subjects
demonstrating earlier resolution of sputum cultures, earlier
radiologic improvement and reductions in BALF cytokine levels
[15–17].
However, little is known about the role of IFN-a and IFN-c on
the control of B.anthracis in vivo. In vitro, B.anthracis is capable of
disrupting IFN signaling. Lethal toxin inhibits LPS mediated
Interferon Response Factor-3 production, a prerequisite for
IFN2a/b production. In addition, B.anthracis inhibits IFN2c
mediated nitric oxide (NO) production and IFN2a mediated
STAT1 activation [6,18]. We have recently described a protective
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Exogenous IFN-b or IFN-c inhibited intracellular B.anthracis
germination and increased macrophage survival for murine and
human alveolar macrophages [18]. Finally, a recent study
documents an essential role for IFN-c producing CD4
+ cells in
the development of effective cell mediated immunity after
vaccination with inactivated B.anthracis spores [19]. Therefore,
the purpose of this study was to determine whether exogenous
IFN-a or IFN-c is capable of protecting mice during infection with
B.anthracis in vivo.
RESULTS
We first wished to establish an in vivo model for pulmonary
anthrax. C57BL/6 mice were administered 10
8 spores 34F2
intratracheally. This resulted in significant pulmonary infiltration
and PMN recruitment into the alveolar space (data not shown) and
an approximate 20% mortality. Saline administration had no
effect on mortality or PMN recruitment (Data not shown).
Quantitative cultures from whole lung performed 30 min after
administration resulted in.90% yield of original inoculums. We
next wished to test the role of endogenous IFN in our model. We
chose STAT1
2/2 mice, as STAT1 is required for IFN-a and IFN-
c signaling. STAT1
2/2 mice had a 2-fold increase in mortality
compared to WT mice (37% vs. 19%) with B.anthracis infection
(Figure 1). This was associated with an increase in the fraction
germinated spores within the lung (Figure 2A) as well as
extrapulmonary spread as assessed by splenic cultures
(Figure 2B). Interestingly, in contrast to WT mice, STAT1
2/2
mice had marked attenuation in systemic levels of IL-6, IL-10 and
IL-12 (Figure 3) suggesting endogenous IFN are required for
maximal innate immune activation and cytokine production
during inhalational anthrax. Finally, STAT1
2/2 mice had no
difference in total lung Myeloperoxidase activity (MPO) (12.5630
vs. 8.168 pg MPO/Lung; p=NS) compared to WT mice,
suggesting little role for STAT1 in controlling PMN recruitment.
Given the requirement of endogenous IFN signaling for optimal
control of germination and inflammatory cytokine production in
vivo, we next wished to assess whether administration of exogenous
IFN-a or IFN-c would improve bacterial control and lethality in
Figure 1. STAT1
2/2 mice have increased susceptibility to B.anthracis.
WT and STAT1
2/2 mice were infected with 10
8 spores B.anthracis
intratracheally and monitored for survival. p=0.13. 8–10 mice/group
doi:10.1371/journal.pone.0000736.g001
Figure 2. STAT1
2/2 mice have increased bacterial burden in lung and spleen. Mice were infected with B.anthracis (10
8) and A. Lungs were
harvested at 24 hrs and the fraction of germinated spores determined by the formula (CFU B.anthracis in lung-CFU B.anthracis lung after heat
treatment{dormant spores})/CFU B.anthracis lung. B. Quantitative culture from spleen harvested at 24 hrs. Serial dilutions were made of whole splenic
homogenate. * p,0.05 compared to WT. N=5/group
doi:10.1371/journal.pone.0000736.g002
Figure 3. STAT1
2/2 mice have impaired cytokine induction during infection with B.anthracis. Mice were administered B.anthracis 10
8 spores/
mouse and plasma harvested at 24 hrs. IL-6/10/12p40 determined by ELISA. N=5/group.
doi:10.1371/journal.pone.0000736.g003
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4 U) intratracheally
with spores slightly increased mortality of B.anthracis infection
compared to spores alone (38% vs. 18%). However, administration
of 1 mg IFN-c with B.anthracis spores resulted in a 100% lethality at
3 days with similar results obtained with 0.2 mg IFN2c (Figure 4).
These effects were specific for the interaction of IFN and
B.anthracis as mice treated with IFN alone had a 100% survival
(data not shown).
We next wished to assess the effect of exogenous IFN on control
of B.anthracis germination. Neither IFN-a nor IFN-c had any effect
on the total number of viable bacteria and spores recovered from
the lung at 24 hrs. However, consistent with previously reported in
vitro data, both IFN-c and IFN-a significantly reduced the fraction
of germinated spores obtained from the lung (Figure 5A) [18]. In
addition, exogenous IFN-c and to a lesser extent IFN-a,
significantly increased extrapulmonary dissemination of B.anthracis
as determined by quantitative cultures from splenic homogenates
(Figure 5B). These changes we not due to alteration in lung PMN
content, as WT, IFN-a and IFN-c treated mice had similar
amounts of MPO activity in whole lung (8.168.5 vs. 10.266.1 vs.
7.264.6 pg MPO/Lung; p=NS) and BALF (Not shown).
The propensity of exogenous IFN to facilitate extrapulmonary
spread of B.anthracis raised the possibility that IFN stimulation
exaggerated the local inflammatory response. Infection with
B.anthracis resulted in marked upregulation of IL-6, IL-10 and
IL-12 in BALF 24 hrs after infection compared to saline treated
controls (Figure 6). Exogenous IFNs, in the absence of infection,
had no effect on BALF IL-6 or IL-10, but did increase BALF levels
of IL-12p40 compared to saline treated controls. This increase in
IL-12p40 was further augmented in the setting of inhalation
anthrax, especially with IFN-c. In addition, exogenous IFNs
attenuated the B.anthracis induction of anti-inflammatory IL-10 in
BALF, with no effect on IL-6. In contrast, IFN resulted in marked
upregulation of systemic IL-6, with no significant effect on IL-10
and IL-12 (Figure 6). Interestingly, levels of systemic IL-6
correlated with splenic bacterial burden (R
2=0.44; p=0.02),
suggesting IL-6 as a potential marker for extrapulmonary spread
of B.anthracis.
Finally, we wished to ascertain whether the changes in
inflammatory cytokine production were associated with alterations
in signaling pathways known to be altered by either B.anthracis or
exogenous IFN. As expected, infection with B.anthracis resulted in
cleavage of MKK3 in BALF cells, representing functional LeTx
activity in vivo. Interestingly, this was attenuated by administration
of exogenous IFN-c (Figure 7A). Similar to our in vitro data,
infection with B.anthracis was only a weak inducer of IFN signaling,
Figure 4. IFN-c increases mortality in mice with inhalational anthrax. C57BL/6 mice were given 10
8 spores 34F2 intratracheally in 100 ml saline. IFN-c
or IFN-a at described doses was added to saline and administered with B.anthracis spores. Mice were subsequently monitored for survival. N=5–7
mice/group.
doi:10.1371/journal.pone.0000736.g004
Figure 5. IFN-c reduces the fraction of germinated spores in the lung. Mice were infected with B.anthracis (10
8)6IFN. A. Lungs were harvested at
24 hrs and the fraction of germinated spores determined by the formula (CFU B.anthracis in lung-CFU B.anthracis lung after heat treatment{dormant
spores})/CFU B.anthracis lung. B. Quantitative culture from spleen harvested at 24 hrs. Serial dilutions were made of whole splenic homogenate. *
p,0.05 compared to WT. N=5/group.
doi:10.1371/journal.pone.0000736.g005
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[18]. Furthermore, infection with B.anthracis inhibited both IFN
induced total STAT1 protein expression as well as IFN induced
phospho
tyr701-STAT1 formation, suggesting the phenotypic effects
induced by exogenous IFN maybe in part due to STAT1
independent IFN signaling.
DISCUSSION
One of the major findings of this paper is the sensitizing role for
exogenous IFN in the treatment of pulmonary anthrax in vivo. Our
group has previously described a protective role for exogenous
Type I and Type II IFN for macrophages infected with B.anthracis
ex-vivo, with exogenous IFNs improving both macrophage viability
and preventing intracellular germination [18]. Interferons appear
to have a similar effect in vivo, with IFN treated mice having
a significant attenuation in the fraction of germinated bacterium
24 hrs after infection. However, this inhibition was associated with
an increase in lethality and extrapulmonary dissemination of
B.anthracis. The finding of a sensitizing role for exogenous IFN,
while surprising, has been described in other infectious models.
Exogenous IFN2c, while improving phagocytosis in vitro and in
vivo, increases mortality in a murine model of invasive aspergillosis
[20]. Similar results have been observed in a murine model of
invasive candidiasis [21]. In similar fashion, IFN2a mediates the
sensitivity to M.tuberculosis in mice, with IFN-a/b treated mice
having higher bacillary loads and increased mortality [22].
There are many potential explanations for this phenomenon.
First, is both IFN2a and IFN2c augment the local inflammatory
response within the lung allowing for loss of pulmonary capillary
integrity and facilitating extrapulmonary dissemination. The
ability of IFNs, especially IFN-c, to attenuate anti-inflammatory
cytokines (IL-10) while maintaining (IL-6) or increasing pro-
inflammatory cytokines (IL-12p40) supports this hypothesis.
Although we can not exclude this is in part mediated by IL-23,
which shares the common IL12p40 subunit, our results are
consistent with the observation that exogenous IL-12 administra-
tion increases lethality in murine candidiasis by further up
regulating endogenous IFN-c production [23,24]. The mechanism
by which IFN mediates these cytokine effects is less clear. Similar
to in vitro data, infection with B.anthracis in vivo results in only mild
induction of IFN signaling as determined by STAT1 phosphor-
ylation. Furthermore, exogenous IFN fails to significantly augment
this activation in the setting of infection with B.anthracis suggesting
a potential for STAT1 independent IFN signaling. While these
effects are not due to changes in PMN recruitment, we can not
exclude these effects are in part due to differential recruitment of
Figure 6. IFN alters the balance of inflammatory cytokines in the lung and serum during infection with B.anthracis. Mice were administered
B.anthracis 10
8 spores/mouse+IFN-c (1 mg/ml), IFN-a (10
4U/ml) or vehicle and BALF and plasma harvested at 24 hrs. IL-6/10/12p40 determined by
ELISA. N=5/group. *p,0.05 compared to WT.-=levels in uninfected mice
doi:10.1371/journal.pone.0000736.g006
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infection with B.anthracis, including lymphocytes and NK cells.
Further studies investigating lineage specific changes in cytokine
production and transcriptional activation would help further
clarify these changes.
One potential mechanism is restoration of MAPK signaling.
Both IFN-a and IFN-c are known to alternatively signal through
MAP kinase family members with resultant inflammatory cytokine
production [25227]. In addition, activation of MAP kinase
members is required for optimal serine phosphorylation of STAT1
[25,28]. A hallmark of B.anthracis LeTx activity is proteolytic
cleavage and inactivation of numerous upstream MKKs, including
MKK3 [3]. This results in impaired host response and attenuated
cytokine production in response to subsequent inflammatory
stimuli [29,30]. Infection with B.anthracis resulted in proteolytic
cleavage of MKK3 in BALF. Interestingly, this was inhibited by
administration of exogenous IFN-c suggesting possible restoration
of MAPK signaling cascades. Given the observation that MKK3 is
required for IL-12 production, this may also explain the
preferential effect for exogenous IFN on increasing IL-12p40
levels [31].
However, the sensitizing effect of IFNs in our model does not
negate a potentially important role for endogenous IFNs in
regulating the host response to B.anthracis. The trend towards
increased mortality, bacterial germination and dissemination and
impaired cytokine production in STAT1
2/2 mice, suggest an
important role for endogenous STAT1 activation in innate
immune activation in inhalational anthrax. This is consistent with
a recent observation that CD4
+ cell mediated IFN2c production
is required for optimal cell mediated immunity to B.anthracis [19].
However, the mild increase in susceptibility in STAT1
2/2 mice,
compared to the highly lethal phenotype for these mice in
M.tuberculosis, may provide additional evidence for a role for STAT
independent signaling of endogenous IFN in B.anthracis [32].
There are limitations to our study. First, these studies used the
34F2 strain (Sterne) of B.anthracis. Although capable of producing
both LeTx and EF, the presence of the former verified by the
cleavage of MKK3 in our mice, it is a capsule deficient strain
(pXO2). This could have significant effects on the ability of IFNs to
alter intracellular germination and survival. Therefore, it would be
imperative for these results to be repeated with a virulent strain of
B.anthracis such as Ames. Another limitation is the use of C57BL/6
mice. These mice are known to be more prone to a vigorous Th1
response and are relatively resistant to infection with B.anthracis
compared to other strains including C3H [33,34]. Therefore, it is
possible exogenous IFNs could have a differential response in
other strains. Finally, the use of STAT1
2/2 mice, while abolishing
all typical Type I and Type II IFN signaling, still leaves JAK-
STAT independent IFN signaling intact. Further studies, in-
cluding replicating these experiments in IFN-a/b and IFN-c
receptor deficient mice as well as administration of exogenous
IFNs to STAT1
2/2 mice, will be required to fully ascertain the
role of STAT independent IFN signaling in inhalational anthrax.
In conclusion, administration of exogenous IFN-c, and to
a lesser extent IFN-a, while attenuating germination, increases
inflammation and extrapulmonary spread of B.anthracis. This is in
part mediated by STAT1 independent IFN signaling. Further
studies are required to determine the role of IFN mediated MAPK
activation in B.anthracis. Further studies are required, especially
with virulent B.anthracis, before IFNs can be used as immunoadju-
vants for inhalational anthrax.
METHODS
Mice
6–8 week old Female C57BL/6 mice were obtained from Jackson
Labs (Strain #00664). Age and sex matched STAT1
2/2 mice,
bred on C57BL/6 background were obtained from Dr. David
Levy at NYU School of Medicine and housed in SPF conditions
till use. All experiments were approved by the NYU School of
Medicine IUCAC.
Preparation of B.anthracis spores
Sterne strain of B.anthracis spores (34F2-Coloroda Serum Compa-
ny) were prepared as previously described [18]. Briefly spores were
allowed to germinate overnight at 37uC in Phage Assay broth
(8 gm Difco Nutrient broth, 015 gm CaCl2, .2 gm MgSO4,
0.05 gm MnSO4, 5 gm NaCl, 10% horse serum). Flasks are then
incubated at 30uC for 3–5 days. Spores were spun down and
washed with sterile H2064. Spores are resuspended in sterile H20
and heat treated at 65uC for 30 minutes to kill any vegetative
spores. Remaining spores are spun down and washed62 in sterile
water and resuspended in sterile H20 at a concentration of 10
9/ml.
Concentration is determined by quantitative cultures.
In vivo infection model
Mice were anesthetized with 2.5% isoflourane and supplemental
oxygen. 100 mlo fB.anthracis spores or control vehicle were inserted
directly into the trachea with a 20 g blunt tip needle. For
experiments with exogenous interferon, 10 ml of IFN2c (provided
by Dr. David Levy), IFN2a (R&D systems) or control vehicle was
mixed with the spores and inserted simultaneously into the lung.
For survival experiments, mice were monitored every 12 hrs for
a total of 30 days or until death/sacrifice.
Quantitative Cultures
Quantitative cultures were made by serial dilutions of whole lung
or spleen homogenized in 0.1% Triton X-100. To determine the
number of ungerminated bacterium, lung homogenate was
incubated at 65C for 30 min, to kill all germinated bacteria.
Figure 7. Effect of IFN and B.athracis on MKK3 and STAT1 signaling.
Mice were administered B.anthracis 10
8 spores/mouse+IFN-c (1 mg/ml),
IFN-a (10
4U/ml) or vehicle and BALF cells harvested at 24 hrs. For
immunoblot. A. Immunoblot for MKK3. B. Immunoblot for phosphor-
Tyr
701 and Total STAT1. Data represent pooled BAL from 5 mice. All
lanes were normalized for protein (50 mg/lane)
doi:10.1371/journal.pone.0000736.g007
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ELISAs for IL-6, IL-10 and IL-12p40 were performed using
commercially available ELISAs (R&D systems). BALF cells were
lysed in NP-40 lysis buffer as previously described [18].
Immunoblot for total and phosphor-STAT1 and MKK3 were
performed on BALF cell lysates as previously described [18]. For
all blots, lanes were normalized for total protein. MPO was
assessed from whole lung homogenates by commercially available
ELISA (Hycult Biotechnologies).
Statistics
Comparisons between groups was performed with non-parametric
T-Test. Survival data was analyzed with Kaplan Meier survival
analysis. All data analyzed with Graph Pad 4.0 statistical software.
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